Critical thinking about adverse drug effects: Lessons from the psychology of risk and medical decision-making for clinical psychopharmacology

Psychotherapy and Psychosomatics

Volumn 77, Issue 4, 2008, Pages 201-208

  Nierenberg, Andrew A ^a   Smoller, Jordan W ^a   Eidelman, Polina ^a   Wu, Yelena P ^a   Tilley, Claire A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adverse drug effects; Psychology of risk; Psychopharmacology

Indexed keywords

CITALOPRAM; FLUOXETINE; OLANZAPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE;

COGNITION; DRUG EFFICACY; DRUG INDUSTRY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; INSULIN RESISTANCE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MENTAL DISEASE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN;

ADVERTISING AS TOPIC; BENZODIAZEPINES; CONFLICT OF INTEREST; DECISION SUPPORT TECHNIQUES; DRUG INDUSTRY; ETHICS, MEDICAL; EVIDENCE-BASED MEDICINE; HUMANS; MARKETING; MENTAL DISORDERS; PIPERAZINES; PROPAGANDA; PSYCHIATRY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; THIAZOLES; UNITED STATES;

EID: 43649104143     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000126071     Document Type: Review

References (59)

1. Devereaux PJ, Yusuf S: The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003;254:105-113.
2. Golder EM, Bilsker D: Evidence-based psychiatry. Can J Psychiatry 1995;40:97-101.
3. Sackett DL: Evidence-based medicine. Semin Perinatol 1997;21:3-5.
4. Sackett DL, Rosenberg WM: On the need for evidence-based medicine. J Public Health Med 1995;17:330-334.
5. Horwitz RI, Singer BH, Makuch RW, Viscoli CM: Can treatment that is helpful on average be harmful to some patients? J Clin Epidemiol 1996;49:395-400.
6. Carroll KM, Nich C, McLellan AT, McKay JR, Rounsaville BJ: 'Research' versus 'real-world' patients: representativeness of participants in clinical trials of treatments for cocaine dependence. Drug Alcohol Depend 1999;54:171-177.
7. Rapaport MH, Frevert T, Babior S, Zisook S, Judd LL: A comparison of demographic variables, symptom profiles, and measurements of functioning in symptomatic volunteers and an outpatient clinical population. Psychopharmacol Bull 1995;31:111-114.
8. Stirman SW, DeRubeis RJ, Crits-Christoph P, Brody PE: Are samples in randomized controlled trials of psychotherapy representative of community outpatients? A new methodology and initial findings. J Consult Clin Psychol 2003;71:963-972.
9. Braslow JT, Duan N, Starks SL, Polo A, Bromley E, Wells KB: Generalizability of studies on mental health treatment and outcomes, 1981 to 1996. Psychiatr Serv 2005;56:1261-1268.
10. Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002;159:469-473.
11. Schelling FA: Clinical trials: deliberations on their essence and value. J Eval Clin Pract 2004;10:291-296.
12. Fava G: The intellectual crisis of psychiatric research. Psychother Psychosom 2006;75:202-208.
13. Wise TN: Curiosity and crisis. Psychother Psychosom 2006;75:199-201.
14. Feinstein AR: Experimental requirements and scientific principles in case-control studies. J Chronic Dis 1985;38:127-133.
15. Sackett DL, Hoey J: Why randomized controlled trials fail but needn't: a new series is launched. CMAJ 2000;162:1301-1302.
16. Redelmeier DA, Shafir E: Medical decision making in situations that offer multiple alternatives. JAMA 1995;273:302-305.
17. Cohen P, Cohen J: The clinician's illusion. Arch Gen Psychiatry 1984;41:1178-1182.
18. Timmermans D: The roles of experience and domain expertise in using numerical and verbal probability terms in medical decisions. Med Decis Making 1994;14:146-156.
19. Kong A, Barnett GO, Mosteller F, Youtz C: How medical professionals evaluate expressions of probability. N Engl J Med 1986;315:740-744.
20. Denig P, Haaijer-Ruskamp FM, Zijsling DH: How physicians choose drugs. Soc Sci Med 1988;27:1381-1386.
21. Tversky A, Kahneman D: Judgment under uncertainty: heuristics and biases. Science 1974;185:1124-1131.
22. Kahneman D: A perspective on judgment and choice: mapping bounded rationality. Am Psychologist 2003;58:697-720.
23. Tversky A, Kahneman D: The framing of decisions and the psychology of choice. Science 1981;211:453-458.
24. Marteau TM: Framing of information: its influence upon decisions of doctors and patients. Br J Soc Psychol 1989;28:89-94.
25. Kraemer HC, Kupfer DJ: Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006;59:990-996.
26. Gigerenzer G: Calculated Risks: How to Know When Numbers Deceive You. New York, Simon &Schuster, 2002.
27. Gigerenzer G, Edwards A: Simple tools for understanding risks: from innumeracy to insight. BMJ 2003;327:741-744.
28. Forrow L, Taylor WC, Arnold RM: Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992;92:121-124.
29. Naylor CD, Chen E, Strauss B: Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-921.
30. Slovic P, Monahan J, MacGregor DM: Violence risk assessment and risk communication: the effects of using actual cases, providing instructions, and employing probability vs. frequency formats. Law Hum Behav 2000;24:271-296.
31. Lavori PW: Placebo control groups in randomized treatment trials: a statistician's perspective. Biol Psychiatry 2000;47:717-723.
32. Bernstein PL: Against the Gods: The Remarkable Story of Risk. New York, Wiley, 1998.
33. Freeman JK, Barnes JH, Summers KH, Szeinbach SL: Modeling physicians' prescribing decisions for patients with panic disorder. J Health Care Mark 1993;13:34-39.
34. Gilovich T, Medvec VH: The experience of regret: what, when, and why. Psychol Rev 1995;102:379-395.
35. Anderson CJ: The psychology of doing nothing: forms of decision avoidance result from reason and emotion. Psychol Bull 2003;129:139-167.
36. Miceli JJ, Shiovitz T, Swift RH, et al: Effects of oral ziprasidone and haloperidol on QTc at clinical and high doses. Biol Psychiatry 2003;53:186S.
37. Heinrich TW, Biblo LA, Schneider J: Torsades de pointes associated with ziprasidone. Psychosomatics 2006;47:264-268.
38. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM: Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887.
39. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847.
40. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ: Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162:1535-1538.
41. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622.
42. Taylor DM, McAskill R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-432.
43. Lieberman JA, Strou TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
44. Preskorn SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol 1998;12(suppl B):S89-S97.
45. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
46. Jefferson JW: Drug interactions - friend or foe? J Clin Psychiatry 1998;59(suppl 4):37-47.
47. Ereshefsky L, Riesenman C, Lam YW: Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996;57(suppl 8):17-24, discussion 25.
48. Stahl SM: Psychopharmacology of Antidepressants. St Louis, Mosby, 1997.
49. Rush AJ, Bose A, Heydorn WE: Naturalistic study of the early psychiatric use of citalopram in the United States. Depress Anxiety 2002;16:121-127.
50. Eli Lilly: Safety information for prozac. 2003. http://www.prozac.com/ common_pages/safety_information.jsp?reqNavId=undefined.
51. Rush AJ, Carmody TJ, Haight BR, Rockett CB, Zisook S: Does pretreatment insomnia or anxiety predict acute response to bupropion SR? Ann Clin Psychiatry 2005;17:1-9.
52. Rush AJ, Trivedi MH, Carmody TJ, Donahue RM, Houser TL, Bolden-Watson C, Batey SR, Ascher JA, Metz A: Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;25:131-138.
53. Rush AJ, Batey SR, Donahue RM, Ascher JA, Carmody TJ, Metz A: Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001;64:81-87.
54. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, Metz A: Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001;62:776-781.
55. Smoller JW, Nierenberg AA: Small numbers, big impact. Harv Rev Psychiatry 1999;7:109-113.
56. Slovic P, Finucane ML, Peters E, MacGregor DG: Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk Anal 2004;24:311-322.
57. Alhakami AS, Slovic P: A psychological study of the inverse relationship between perceived risk and perceived benefit. Risk Anal 1994;14:1085-1096.
58. Hendrickx L, Vlek C, Oppewal H: Relative importance of scenario information and frequency information in the judgment of risk. Acta Psychol 1989;72:41-63.
59. Krishnan R: Through the looking glass: risk perception. Biol Psychiatry 2005;57:1477-1478.